Drug Profile
V 19
Alternative Names: V19Latest Information Update: 22 Aug 2002
Price :
$50
*
At a glance
- Originator GLYCODesign
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 22 Aug 2002 Discontinued - Phase-II for Thrombosis in USA (unspecified route)
- 13 Sep 2000 No-Development-Reported for Thrombosis in USA (Unknown route)
- 30 Dec 1998 Phase-II clinical trials for Thrombosis in USA (Unknown route)